Know Cancer

or
forgot password

Effectiveness and Safety as Well as Adherence of the "S3 Guidelines for the Treatment of Prostate Cancer" in the Treatment of Patients of Patients With Firmagon®


N/A
18 Years
95 Years
Open (Enrolling)
Male
Prostate Cancer

Thank you

Trial Information

Effectiveness and Safety as Well as Adherence of the "S3 Guidelines for the Treatment of Prostate Cancer" in the Treatment of Patients of Patients With Firmagon®


Inclusion Criteria:



- advanced hormone-dependent prostate cancer with no other previous hormone therapy for
whom - irrespectively of this NIS -the use of Firmagon® is intended

Exclusion Criteria:

- contraindication for Degarelix

Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Prospective

Outcome Measure:

PSA-/Testosterone Level

Outcome Time Frame:

12 months

Safety Issue:

No

Principal Investigator

Leopold Durner, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

UCM GmbH

Authority:

Germany: Federal Institute for Drugs and Medical Devices

Study ID:

UCM12-01

NCT ID:

NCT01710098

Start Date:

June 2012

Completion Date:

June 2014

Related Keywords:

  • Prostate Cancer
  • testosterone
  • S3-Adherence
  • Quality of Life
  • Prostatic Neoplasms

Name

Location